OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Sharma on Key Trials Within the Urothelial Cancer Therapeutic Paradigm

November 7th 2024

Janaki Neela Sharma, MD, discusses which trials have shifted the therapeutic paradigm for patients with urothelial cancer.

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

November 7th 2024

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Dr Ashraf on the Utility of T-DXd in HER2-Mutated NSCLC

November 7th 2024

Noman Ashraf, MD, discusses notable data seen with T-DXd treatment in previously treated HER2-mutated and -overexpressing non–small cell lung cancer.

Dr Feldman on the Significance of the HER2-Low Classification in HER2+ Breast Cancer

November 7th 2024

Sheldon M. Feldman, MD, discusses the significance of the new classification of HER2-low breast cancer and how this affects HER2+ breast cancer treatment

Dr Bardia on Findings From DESTINY-Breast06 in HER2-Low Breast Cancer

November 6th 2024

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

Dr Baik on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLC

November 6th 2024

Christina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.

Dr Zakalik on the Role of Genetic Testing to Guide Breast Cancer Treatment

November 6th 2024

Dana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.

Dr Fisher on Mechanisms of Resistance to Pirtobrutinib in CLL

November 6th 2024

David C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL

Dr Kalinsky on the Future of Treatment With T-DXd in HER2+ Breast Cancer

November 5th 2024

Kevin Kalinsky, MD, MS, discusses future treatment directions with T-DXd in breast cancer, as well as the evolving role of HER2 classification.

Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors

November 5th 2024

Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.

Dr Randall on the Effect of Socioeconomic Factors in Pediatric Nonmetastatic Osteosarcoma

November 5th 2024

R. Lor Randall, MD, FACS, discusses the impact of race, ethnicity, and socioeconomic factors on outcomes in pediatric patients with nonmetastatic osteosarcoma.

Dr Haggstrom on Future Research Directions in EGFR+ and ALK+ NSCLC

November 5th 2024

Daniel E. Haggstrom, MD, discusses future research directions within EGFR-and ALK-mutant non–small cell lung cancer.

Dr Krishnamurthy on Treatment Sequencing Based on Mutation Status in HR+/HER2– Breast Cancer

November 5th 2024

Jairam Krishnamurthy, MD, FACP, discusses the use of mutation status to inform treatment sequencing in HR-positive, HER2-negative metastatic breast cancer.

Dr Lotan on Ongoing Research With Novel Agents in BCG-Unresponsive NMIBC

November 5th 2024

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCC

November 5th 2024

Thomas Westbrook, MD, discusses the investigation of approved ccRCC treatments in patients with non-ccRCC.

Dr Moore on the Evolving Treatment Landscape for Platinum-Resistant Ovarian Cancer

November 4th 2024

Kathleen N. Moore, MD, MS, discusses the evolving landscape in managing platinum-resistant ovarian cancer.

Dr Bekaii-Saab on the Role of Liquid and Tissue Biopsies for Newly Diagnosed GI Cancers

November 4th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the role of liquid and tissue biopsies in newly diagnosed gastrointestinal cancers.

Dr Graham on the Evaluation of RAGE Inhibition for Therapy-Related Cardiotoxicity in Breast Cancer

November 1st 2024

Deena Mary Atieh Graham, MD, discusses a pilot study evaluating RAGE inhibition to reduce therapy-related cardiotoxicity in early-stage breast cancer.

Dr Kotecha on the FDA Approval of Optune Lua in Metastatic NSCLC

October 31st 2024

Rupesh Rajesh Kotecha, MD, discusses the FDA approval for Optune Lua in metastatic non–small cell lung cancer.

Dr Braun on Advancements in Biomarker Development in RCC

October 31st 2024

David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.